文献速递肝病消化道肿瘤与早癌

精准医学时代肝细胞癌的危险因素与预防

Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.
PubMed 文献 · J Hepatol · 2017-10-06

综述指出,病毒性或代谢性病因所致慢性纤维化肝病患者肝细胞癌(HCC)风险高,完全切除或消融后残留肝脏的致癌微环境仍可导致复发。临床实践指南推荐的「一刀切」筛查在目标人群中应用不足20%,超声和甲胎蛋白筛查性能欠佳;新生物标志物、影像及临床和分子风险评分有望实现精准风险预测与个体化筛查,他汀类、抗糖尿病药及选择性分子靶向药等化学预防策略正在演变,但临床验证受限于癌症发展过程漫长、研究成本高。

要点

  • 慢性纤维化肝病患者HCC风险高,完全切除或消融后残留肝脏致癌微环境仍可致复发。
  • 指南推荐的「一刀切」筛查在目标人群中应用不足20%,超声和甲胎蛋白筛查性能欠佳。
  • 临床和分子HCC风险评分可实现精准风险预测和个体化筛查,最大化成本效益。

核心结论

  • 个体化HCC风险预测有望通过实现针对高危患者的精准化学预防,克服癌症发展过程漫长、研究成本高的挑战,并大幅改善HCC的不良预后。

研究设计与样本

  • 综述,未报告系统检索范围与样本量。

主要发现

  • 临床实践指南推荐的「一刀切」HCC筛查在目标人群中应用不足20%,超声和甲胎蛋白等筛查方式性能欠佳。
  • 对于病毒治愈后的慢性丙型肝炎患者或非肝硬化非酒精性脂肪性肝病等新兴高风险人群,最佳筛查策略仍存争议。
  • 新HCC生物标志物和影像学方法可能提高HCC检测的灵敏度和特异度。
  • 临床和分子HCC风险评分可实现精准风险预测,继而进行个体化HCC筛查,最大化成本效益并优化有限医疗资源配置。
  • 流行病学和实验研究已发现候选化学预防靶点和疗法,包括他汀类、抗糖尿病药和选择性分子靶向药,但其临床验证受限于癌症发展过程漫长、需长期高成本研究。

局限性

  • 临床实践指南推荐的「一刀切」HCC筛查在目标人群中应用不足20%,超声和甲胎蛋白等筛查方式性能欠佳。
  • 对于病毒治愈后的慢性丙型肝炎患者或非肝硬化非酒精性脂肪性肝病等新兴高风险人群,最佳筛查策略仍存争议。
  • 候选化学预防疗法的临床验证受限于癌症发展过程漫长、需长期高成本研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients who develop chronic fibrotic liver disease, caused by viral or metabolic aetiologies, are at a high risk of developing hepatocellular carcinoma (HCC). Even after complete HCC tumour resection or ablation, the carcinogenic tissue microenvironment in the remnant liver can give rise to recurrent de novo HCC tumours, which progress into incurable, advanced-stage disease in most patients. Thus, early detection and prevention of HCC development is, in principle, the most impactful strategy to improve patient prognosis. However, a "one-size-fits-all" approach to HCC screening for early tumour detection, as recommended by clinical practice guidelines, is utilised in less than 20% of the target population, and the performance of screening modalities, including ultrasound and alpha-fetoprotein, is suboptimal. Furthermore, optimal screening strategies for emerging at-risk patient populations, such as those with chronic hepatitis C after viral cure, or those with non-cirrhotic, non-alcoholic fatty liver disease remain controversial. New HCC biomarkers and imaging modalities may improve the sensitivity and specificity of HCC detection. Clinical and molecular HCC risk scores will enable precise HCC risk prediction followed by tailoured HCC screening of individual patients, maximising cost-effectiveness and optimising allocation of limited medical resources. Several aetiology-specific and generic HCC chemoprevention strategies are evolving. Epidemiological and experimental studies have identified candidate chemoprevention targets and therapies, including statins, anti-diabetic drugs, and selective molecular targeted agents, although their clinical testing has been limited by the lengthy process of cancer development that requires long-term, costly studies. Individual HCC risk prediction is expected to overcome the challenge by enabling personalised chemoprevention, targeting high-risk patients for precision HCC prevention and substantially improving the dismal prognosis of HCC.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Fujiwara N, Friedman SL, Goossens N, et al. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol. 2017. PMID: 28989095. doi:10.1016/j.jhep.2017.09.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。